Further Darzalex results extend hope for PFS in MyelomaEarlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its Share XFurther Darzalex results extend hope for PFS in Myelomahttps://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/
